[go: up one dir, main page]

WO1998039425A3 - Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes - Google Patents

Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes Download PDF

Info

Publication number
WO1998039425A3
WO1998039425A3 PCT/US1998/004155 US9804155W WO9839425A3 WO 1998039425 A3 WO1998039425 A3 WO 1998039425A3 US 9804155 W US9804155 W US 9804155W WO 9839425 A3 WO9839425 A3 WO 9839425A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutant
toxin
mutants
expression
fusion proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/004155
Other languages
English (en)
Other versions
WO1998039425A2 (fr
Inventor
David M Neville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to EP98910152A priority Critical patent/EP0968282A2/fr
Priority to AU64459/98A priority patent/AU736501B2/en
Priority to CA002283497A priority patent/CA2283497A1/fr
Publication of WO1998039425A2 publication Critical patent/WO1998039425A2/fr
Publication of WO1998039425A3 publication Critical patent/WO1998039425A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nouveau vecteur navette permettant l'expression, dans Corynebacterium, de mutants de toxine et de proteines hybrides de toxine, produits par génie génétique. Cette invention concerne également un Pichia pastoris mutant, un procédé de production de ce mutant, et un procédé permettant l'expression dans la forme mutante de Pichia pastoris, des mutants de toxine et des protéines hybrides de toxine produits par génie génétique. On décrit également une cellule ovarienne de hamster chinois mutant, une cellule d'insecte mutant, un procédé de production de ces mutants et un procédé permettant l'expression dans les cellules de mutants, des mutants de toxine et des protéines hybrides de toxine produits par génie génétique.
PCT/US1998/004155 1997-03-05 1998-03-05 Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes Ceased WO1998039425A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98910152A EP0968282A2 (fr) 1997-03-05 1998-03-05 Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes
AU64459/98A AU736501B2 (en) 1997-03-05 1998-03-05 Novel vectors and expression methods for producing mutant proteins
CA002283497A CA2283497A1 (fr) 1997-03-05 1998-03-05 Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3719697P 1997-03-05 1997-03-05
US60/037,196 1997-03-05

Publications (2)

Publication Number Publication Date
WO1998039425A2 WO1998039425A2 (fr) 1998-09-11
WO1998039425A3 true WO1998039425A3 (fr) 1999-01-14

Family

ID=21892966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/004155 Ceased WO1998039425A2 (fr) 1997-03-05 1998-03-05 Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes

Country Status (4)

Country Link
EP (1) EP0968282A2 (fr)
AU (1) AU736501B2 (fr)
CA (1) CA2283497A1 (fr)
WO (1) WO1998039425A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
US7125553B1 (en) 1996-04-15 2006-10-24 The United States of America as represented by the Department of Health and Human Services c/o Centers for Disease Control and Prevention Methods of inducing immune tolerance using immunotoxins
CA2284079C (fr) 1997-03-05 2009-05-12 David M. Neville Nouvelles immunotoxines et nouveaux procedes d'induction de tolerance immunitaire
CA2409746C (fr) * 2000-05-18 2014-11-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Proteines de fusion d'immunotoxines et leurs moyens d'expression
WO2016049510A2 (fr) * 2014-09-25 2016-03-31 The General Hospital Corporation Administration ciblée, à base de cellules, d'exotoxine de pseudomonas

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217327A2 (fr) * 1985-09-30 1987-04-08 Sumitomo Pharmaceuticals Company, Limited Séquence d'ADN codant pour une variante du facteur d'élongation 2
WO1987002987A1 (fr) * 1985-11-13 1987-05-21 Murphy John R Adn modifie par un codon cys
EP0332174A2 (fr) * 1988-03-08 1989-09-13 The University Of Wyoming Agents cellulaires cytotoxiques spécifiques
WO1991013157A1 (fr) * 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Plasmide navette pour 'escherichia coli' et mycobacteria
DE4024187A1 (de) * 1990-07-30 1992-02-06 Biotechnolog Forschung Gmbh Oligonucleotid-gerichtete mutagenese von plasmiden
WO1992013562A1 (fr) * 1991-02-11 1992-08-20 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Immunotoxine possedant une activite de suppression de cellules t in vivo
WO1993015113A1 (fr) * 1992-01-24 1993-08-05 Tanox Biosystems, Inc. Immunotoxine comportant une cytotoxine dotee d'un residu de cysteine non appaire a l'interieur ou a proximite de son site de liaison a un recepteur
EP0616034A2 (fr) * 1993-03-05 1994-09-21 American Cyanamid Company Nouveau plasmide pour la production de la protéine CRM et de la toxine de la diphthérie
WO1995033481A1 (fr) * 1994-06-08 1995-12-14 President And Fellows Of Harvard College Vaccins anti-toxine diphterique portant un domaine r mutant
WO1996032137A2 (fr) * 1995-04-14 1996-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Techniques de declenchement d'une tolerance immunitaire a l'aide d'immunotoxine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217327A2 (fr) * 1985-09-30 1987-04-08 Sumitomo Pharmaceuticals Company, Limited Séquence d'ADN codant pour une variante du facteur d'élongation 2
WO1987002987A1 (fr) * 1985-11-13 1987-05-21 Murphy John R Adn modifie par un codon cys
EP0332174A2 (fr) * 1988-03-08 1989-09-13 The University Of Wyoming Agents cellulaires cytotoxiques spécifiques
WO1991013157A1 (fr) * 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Plasmide navette pour 'escherichia coli' et mycobacteria
DE4024187A1 (de) * 1990-07-30 1992-02-06 Biotechnolog Forschung Gmbh Oligonucleotid-gerichtete mutagenese von plasmiden
WO1992013562A1 (fr) * 1991-02-11 1992-08-20 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Immunotoxine possedant une activite de suppression de cellules t in vivo
WO1993015113A1 (fr) * 1992-01-24 1993-08-05 Tanox Biosystems, Inc. Immunotoxine comportant une cytotoxine dotee d'un residu de cysteine non appaire a l'interieur ou a proximite de son site de liaison a un recepteur
EP0616034A2 (fr) * 1993-03-05 1994-09-21 American Cyanamid Company Nouveau plasmide pour la production de la protéine CRM et de la toxine de la diphthérie
WO1995033481A1 (fr) * 1994-06-08 1995-12-14 President And Fellows Of Harvard College Vaccins anti-toxine diphterique portant un domaine r mutant
WO1996032137A2 (fr) * 1995-04-14 1996-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Techniques de declenchement d'une tolerance immunitaire a l'aide d'immunotoxine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CREGG J M ET AL: "3. Development of the methylotrophic yeast, Pichia pastoris, as a host system for the production of foreign proteins", DEVELOPMENTS IN INDUSTRIAL MICROBIOLOGY (JOURNAL OF INDUSTRIAL MICROBIOLOGY, SUPPL. NO. 3), vol. 29, 1988, pages 33 - 41, XP002082180 *
KIMATA Y ET AL.: "Expression of non-ADP-ribosylatable, diphteria toxin-resistant elongation factor 2 in Saccharomyces cerevisiae", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 191, no. 3, 31 March 1993 (1993-03-31), ORLANDO, FL US, pages 1145 - 1151, XP002082179 *
PERENTESIS J P ET AL: "PROTEIN TOXIN INHIBITORS OF PROTEIN SYNTHESIS", BIOFACTORS, vol. 3, no. 3, January 1992 (1992-01-01), OXFORD GB, pages 173 - 184, XP000611278 *

Also Published As

Publication number Publication date
WO1998039425A2 (fr) 1998-09-11
AU6445998A (en) 1998-09-22
CA2283497A1 (fr) 1998-09-11
EP0968282A2 (fr) 2000-01-05
AU736501B2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
US5635517B1 (en) Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CA2114353A1 (fr) Vecteurs d'expression codant des proteines de fusion bispecifiques et methodes de production de proteines de fusion bispecifiques biologiquement actives dans des cellules de mammiferes
NZ303425A (en) Method of preparing a heteromultimer polypeptide having two polypeptides meeting at an interface; the first polypeptide containing a protuberance and/or the second polypeptide containing a cavity which fits together
AU7673796A (en) Compositions and methods for producing heterologous polypeptides in pichia methanolica
GB2332573B (en) Method for producing fuse element and fuse element produced by the same
CA2296067A1 (fr) Sequence d'acides nucleiques et procede pour exprimer, de maniere selective, une proteine dans une cellule ou un tissu cible
CS15691A3 (en) High-pressure coupling, method of high-pressure connexion manufacture and machine for high-pressure coupling assembly
PL343509A1 (en) Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU1977192A (en) Method of producing a shaped shoe part from a strip of fabric, and a shaped shoe part produced by this method
CA2201142A1 (fr) Liaison a rotule et son procede de production
ZA987151B (en) Method and apparatus for predictive parameter control with loop delay.
EP0960939A3 (fr) Protéines doublemment étiquettées et leurs utilisations
WO2003032095A3 (fr) Systeme de programmation de machines de traitement chimique
HUP9601578A3 (en) Security document, method for producing it as well as security element and method for producing it
EP1741718A3 (fr) Expression de lipoproteins
WO1998039425A3 (fr) Nouveaux vecteurs et procedes d'expression utiles pour produire des proteines mutantes
EP0892365A3 (fr) Méthode et système pour définir le passage en mouvement d'un objet multimedia
AUPN558295A0 (en) Switching regulator, method, and control circuit therefor
EP0726944A4 (fr) Proteines glycosylees et non glycosylees, bactericides et augmentant la permeabilite, et procede de production
AU2617899A (en) Method for producing optically active amino alcohols
EP0680075A4 (fr) Electrode pour la production de plasma, element d'enfouissement d'electrode, et procede de fabrication de l'electrode et de l'element.
AU2840499A (en) Novel woven fabric, method for making same, and resulting garments
GB2316093B (en) Sinter joining method and sintered composite member produced by same
AU9024298A (en) Improved method for making cyclohexanol and cyclohexanone
GB9423404D0 (en) Production of nisin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 64459/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2283497

Country of ref document: CA

Ref country code: CA

Ref document number: 2283497

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998910152

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998910152

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538712

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09380483

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 64459/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998910152

Country of ref document: EP